Respiratory Syncytial Virus (RSV) News and Research

RSS
Respiratory syncytial virus (RSV) causes mild, cold-like symptoms in adults and older children. However, it can cause serious problems in young babies, including pneumonia and severe breathing problems. In rare cases it can lead to death. Premature babies and those with other health problems have the highest risk. A child with RSV may have a fever, stuffy nose, cough and trouble breathing. Tests can tell if your child has the virus.
Alnylam Pharmaceuticals publishes ALN-RSV01 Phase IIa study results

Alnylam Pharmaceuticals publishes ALN-RSV01 Phase IIa study results

Quidel receives FDA clearance for QuickVue RSV 10 immunoassay test

Quidel receives FDA clearance for QuickVue RSV 10 immunoassay test

Novavax announces positive results from pre-clinical toxicology study of RSV vaccine candidate

Novavax announces positive results from pre-clinical toxicology study of RSV vaccine candidate

Alnylam second-quarter revenues increase to $26.6 million

Alnylam second-quarter revenues increase to $26.6 million

Investment report on Novavax

Investment report on Novavax

Motavizumab should not be licensed for marketing: FDA Antiviral Drugs Advisory Committee

Motavizumab should not be licensed for marketing: FDA Antiviral Drugs Advisory Committee

Effective infant vaccina­tion against pneumonia needed in sub-Saharan Africa

Effective infant vaccina­tion against pneumonia needed in sub-Saharan Africa

RSV appears to be predominant among Kenyan children hospitalized with severe pneumonia: Study

RSV appears to be predominant among Kenyan children hospitalized with severe pneumonia: Study

Health Canada grants Response Biomedical Class 3 Medical Device license for RAMP RSV Assay

Health Canada grants Response Biomedical Class 3 Medical Device license for RAMP RSV Assay

Alnylam Pharmaceuticals reports consolidated financial results for first quarter 2010

Alnylam Pharmaceuticals reports consolidated financial results for first quarter 2010

Discovery Labs reports first-quarter results, updates on Surfaxin and key pipeline programs

Discovery Labs reports first-quarter results, updates on Surfaxin and key pipeline programs

Pevion Biotech to present positive results of PEV4 RSV vaccine candidate at Vaccine Innovation Meeting

Pevion Biotech to present positive results of PEV4 RSV vaccine candidate at Vaccine Innovation Meeting

Discovery Laboratories reports net loss of $6.1M for fourth-quarter 2009

Discovery Laboratories reports net loss of $6.1M for fourth-quarter 2009

Alnylam Pharmaceuticals initiates ALN-RSV01 Phase IIb trial in adult lung transplant patients for RSV infection

Alnylam Pharmaceuticals initiates ALN-RSV01 Phase IIb trial in adult lung transplant patients for RSV infection

Novavax to discontinue collaboration agreement with ROVI Pharmaceuticals

Novavax to discontinue collaboration agreement with ROVI Pharmaceuticals

Clinical results of MedImmune's pivotal trial for motavizumab published

Clinical results of MedImmune's pivotal trial for motavizumab published

Researchers develop automated system to differentiate strains of influenza

Researchers develop automated system to differentiate strains of influenza

Respiratory syncytial virus, the most common cause of pneumonia in children

Respiratory syncytial virus, the most common cause of pneumonia in children

MedImmune to develop and commercialize Trellis Bioscience's anti-RSV antibodies

MedImmune to develop and commercialize Trellis Bioscience's anti-RSV antibodies

FDA provides marketing clearance for Prodesse's ProParaflu+ assay

FDA provides marketing clearance for Prodesse's ProParaflu+ assay